Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Speciale sessie tijdens CROI 2020 gewijd aan COVID-19
mrt 2020 | Longoncologie, Virale infecties